{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:16:11Z","timestamp":1792887371924,"version":"4.5.0"},"reference-count":54,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.2967\/jnumed.123.266463","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T17:46:00Z","timestamp":1714067160000},"page":"829-837","source":"Crossref","is-referenced-by-count":28,"title":["Evaluation of Neurodegenerative Disorders with Amyloid-\u03b2, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls"],"prefix":"10.2967","volume":"65","author":[{"given":"Brian J.","family":"Burkett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024060510401911000_65.6.829.1","unstructured":"The Global Dementia Observatory Reference Guide. World Health Organization; 2018."},{"key":"2024060510401911000_65.6.829.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2017.03.002"},{"key":"2024060510401911000_65.6.829.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263194"},{"key":"2024060510401911000_65.6.829.4","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000004251"},{"key":"2024060510401911000_65.6.829.5","first-page":"100155","article-title":"Imaging pathological tau in atypical parkinsonisms: a review","volume":"7","author":"Mena","year":"2022","journal-title":"Clin Park Relat Disord."},{"key":"2024060510401911000_65.6.829.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2024060510401911000_65.6.829.7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1474-4422(21)00412-9","article-title":"2021 marks a new era for Alzheimer\u2019s therapeutics","volume":"21","author":"Kantarci","year":"2022","journal-title":"Lancet Neurol."},{"key":"2024060510401911000_65.6.829.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002923"},{"key":"2024060510401911000_65.6.829.9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajp.2019.07.001","article-title":"Clinical utility of 18F-FDG-PET\/MRI brain in dementia: preliminary experience from a geriatric clinic in South India","volume":"44","author":"Mukku","year":"2019","journal-title":"Asian J Psychiatr."},{"key":"2024060510401911000_65.6.829.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3761-x"},{"key":"2024060510401911000_65.6.829.11","unstructured":"Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s Disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Association website. https:\/\/aaic.alz.org\/diagnostic-criteria.asp#drafts. Accessed April 8, 2024."},{"key":"2024060510401911000_65.6.829.12","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7079"},{"key":"2024060510401911000_65.6.829.13","doi-asserted-by":"publisher","DOI":"10.1148\/rg.345140009"},{"key":"2024060510401911000_65.6.829.14","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-5416-4_16"},{"key":"2024060510401911000_65.6.829.15","first-page":"102","article-title":"The sensitivity and specificity of F-DOPA PET in a movement disorder clinic","volume":"6","author":"Ibrahim","year":"2016","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2024060510401911000_65.6.829.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.120618"},{"key":"2024060510401911000_65.6.829.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.174615"},{"key":"2024060510401911000_65.6.829.18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13024-023-00637-0","article-title":"Anti-amyloid therapies for Alzheimer disease: finally, good news for patients","volume":"18","author":"Ramanan","year":"2023","journal-title":"Mol Neurodegener."},{"key":"2024060510401911000_65.6.829.19","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis."},{"key":"2024060510401911000_65.6.829.20","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2"},{"key":"2024060510401911000_65.6.829.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"2024060510401911000_65.6.829.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2024060510401911000_65.6.829.23","unstructured":"Vizamyl\u2122 flutemetamol F 18 injection. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203137s008lbl.pdf. Revised February 2017. Accessed April 8, 2024."},{"key":"2024060510401911000_65.6.829.24","unstructured":"Amyvid (florbetapir F 18 injection) for intravenous use. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202008s000lbl.pdf. Revised April 2012. Accessed April 8, 2024."},{"key":"2024060510401911000_65.6.829.25","unstructured":"NEURACEQ (florbetaben F 18 injection), for intravenous use. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204677s000lbl.pdf. Revised March 2014. Accessed April 8, 2024."},{"key":"2024060510401911000_65.6.829.26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-017-2661-z","article-title":"Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors","volume":"136","author":"Johnson","year":"2018","journal-title":"J Neurooncol."},{"key":"2024060510401911000_65.6.829.27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jalz.2019.03.016","article-title":"Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease","volume":"15","author":"Lowe","year":"2019","journal-title":"Alzheimers Dement."},{"key":"2024060510401911000_65.6.829.28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","article-title":"Tau-positron emission tomography correlates with neuropathology findings","volume":"16","author":"Lowe","year":"2020","journal-title":"Alzheimers Dement."},{"key":"2024060510401911000_65.6.829.29","doi-asserted-by":"crossref","first-page":"e1916439","DOI":"10.1001\/jamanetworkopen.2019.16439","article-title":"Association of longitudinal \u03b2-amyloid accumulation determined by positron emission tomography with clinical and cognitive decline in adults with probable Lewy body dementia","volume":"2","author":"Nedelska","year":"2019","journal-title":"JAMA Netw Open."},{"key":"2024060510401911000_65.6.829.30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-190699","article-title":"Longitudinal amyloid-\u03b2 PET in atypical Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"74","author":"Whitwell","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"2024060510401911000_65.6.829.31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol."},{"key":"2024060510401911000_65.6.829.32","unstructured":"TAUVID\u2122 (flortaucipir F 18 injection), for intravenous use. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212123s000lbl.pdf. Revised May 2020. Accessed April 8, 2024."},{"key":"2024060510401911000_65.6.829.33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-021-05673-w","article-title":"International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer\u2019s disease","volume":"49","author":"Tian","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401911000_65.6.829.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263196"},{"key":"2024060510401911000_65.6.829.35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3233\/JAD-230032","article-title":"Comparing tau PET visual interpretation with tau PET quantification, cerebrospinal fluid biomarkers, and longitudinal clinical assessment","volume":"93","author":"Chen","year":"2023","journal-title":"J Alzheimers Dis."},{"key":"2024060510401911000_65.6.829.36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"2024060510401911000_65.6.829.37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12149-017-1205-0","article-title":"Uptake of AV-1451 in meningiomas","volume":"31","author":"Bruinsma","year":"2017","journal-title":"Ann Nucl Med."},{"key":"2024060510401911000_65.6.829.38","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx320"},{"key":"2024060510401911000_65.6.829.39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007739"},{"key":"2024060510401911000_65.6.829.40","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s43587-022-00219-7","article-title":"Deep learning-based brain age prediction in normal aging and dementia","volume":"2","author":"Lee","year":"2022","journal-title":"Nat Aging."},{"key":"2024060510401911000_65.6.829.41","unstructured":"FLUORODOPA F 18 injection, for intravenous use. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/200655s000lbl.pdf. Revised October 2019. Accessed April 8, 2024."},{"key":"2024060510401911000_65.6.829.42","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"2024060510401911000_65.6.829.43","first-page":"61","article-title":"The differential diagnosis and treatment of atypical parkinsonism","volume":"113","author":"Levin","year":"2016","journal-title":"Dtsch Arztebl Int."},{"key":"2024060510401911000_65.6.829.44","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"2024060510401911000_65.6.829.45","doi-asserted-by":"crossref","first-page":"674063","DOI":"10.1155\/2014\/674063","article-title":"6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses","volume":"2014","author":"Pretze","year":"2014","journal-title":"BioMed Res Int."},{"key":"2024060510401911000_65.6.829.46","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/WNL.55.10.1575","article-title":"18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies","volume":"55","author":"Hu","year":"2000","journal-title":"Neurology."},{"key":"2024060510401911000_65.6.829.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1904-y"},{"key":"2024060510401911000_65.6.829.48","first-page":"1760","article-title":"Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP\/SPECT and fluorine-18-FDOPA\/PET","volume":"37","author":"Ishikawa","year":"1996","journal-title":"J Nucl Med."},{"key":"2024060510401911000_65.6.829.49","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00943-6"},{"key":"2024060510401911000_65.6.829.50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2214\/AJR.19.21088","article-title":"Optimizing the diagnosis of parkinsonian syndromes with 123I-ioflupane brain SPECT","volume":"213","author":"Banks","year":"2019","journal-title":"AJR."},{"key":"2024060510401911000_65.6.829.51","doi-asserted-by":"publisher","DOI":"10.1021\/ACSCHEMNEURO.7B00252\/ASSET\/IMAGES\/LARGE\/CN-2017-002523_0001.JPEG"},{"key":"2024060510401911000_65.6.829.52","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.chembiol.2021.04.005","article-title":"The chemical tools for imaging dopamine release","volume":"28","author":"Post","year":"2021","journal-title":"Cell Chem Biol."},{"key":"2024060510401911000_65.6.829.53","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41386-020-00866-7","article-title":"A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach","volume":"46","author":"Veronese","year":"2021","journal-title":"Neuropsychopharmacology."},{"key":"2024060510401911000_65.6.829.54","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not002"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:43:44Z","timestamp":1717609424000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.2967\/jnumed.123.266463"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266463","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}